Medicare Enrolled
Dr. David Defeo, M.D.
Pulmonary Disease · Winston Salem, NC
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Defeo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Defeo?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Defeo
Dr. David Defeo is a pulmonary disease specialist in Winston Salem, NC, with 20 years of NPI registration. Based on federal Medicare data, Dr. Defeo performed 1,766 Medicare services across 1,586 unique beneficiaries.
Between the years covered by Open Payments, Dr. Defeo received a total of $5,682 from 54 pharmaceutical and/or device companies across 337 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Defeo is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 15% volume in NC
$5,682 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,766
Medicare services
Top 15% in NC for pulmonary disease
1,586
Unique beneficiaries
$73
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~88 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
309 | $15 | $48 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
218 | $88 | $150 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
185 | $27 | $56 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
172 | $119 | $200 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
110 | $16 | $45 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
82 | $154 | $855 |
| New patient office visit, complex (60-74 min) | 72 | $150 | $284 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
67 | $35 | $70 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
61 | $24 | $55 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
57 | $12 | $25 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
56 | $14 | $25 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
49 | $59 | $100 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
45 | $447 | $1,200 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
44 | $9 | $31 |
| Lung cancer screening counseling visit A visit to discuss the need for lung cancer screening using a low-dose CT scan. This service is used to determine eligibility and facilitate shared decision making. |
40 | $26 | $80 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
39 | $8 | $30 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
35 | $90 | $169 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
32 | $117 | $226 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
30 | $452 | $1,300 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
28 | $53 | $100 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
22 | $50 | $100 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
13 | $132 | $303 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$5,682
Total received (2018-2024)
Avg $812/year across 7 years
Top 31% in NC for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
54
Companies
337
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,682 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,081
2023
$1,145
2022
$814
2021
$724
2020
$290
2019
$543
2018
$1,086
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$141
United Therapeutics Corporation
$112
Boehringer Ingelheim Pharmaceuticals, Inc.
$92
ZOLL Respicardia, Inc.
$85
Regeneron Healthcare Solutions, Inc.
$78
GlaxoSmithKline, LLC.
$63
Vifor Pharma, Inc.
$61
Insmed, Inc.
$43
Merck Sharp & Dohme LLC
$42
Gilead Sciences, Inc.
$39
Mallinckrodt Hospital Products Inc.
$38
Philips North America LLC
$35
GENZYME CORPORATION
$30
Mylan Specialty L.P.
$29
INOGEN, INC.
$25
CSL Behring
$25
Actelion Pharmaceuticals US, Inc.
$22
Takeda Pharmaceuticals U.S.A., Inc.
$19
Grifols USA, LLC
$19
Avadel CNS Pharmaceuticals, LLC
$18
Lilly USA, LLC
$17
Amgen Inc.
$17
PFIZER INC.
$16
Electromed, Inc.
$15
Top 3 companies account for 32.0% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$727
AstraZeneca Pharmaceuticals LP
$701
Boehringer Ingelheim Pharmaceuticals, Inc.
$652
Mallinckrodt Hospital Products Inc.
$286
Gilead Sciences, Inc.
$255
Grifols USA, LLC
$233
United Therapeutics Corporation
$229
Sunovion Pharmaceuticals Inc.
$219
Mylan Specialty L.P.
$180
Actelion Pharmaceuticals US, Inc.
$149
Regeneron Healthcare Solutions, Inc.
$143
GENZYME CORPORATION
$134
Takeda Pharmaceuticals U.S.A., Inc.
$116
Genentech USA, Inc.
$112
Insmed, Inc.
$110
Philips Electronics North America Corporation
$89
ZOLL Respicardia, Inc.
$85
Merck Sharp & Dohme LLC
$85
Electromed, Inc.
$84
Mallinckrodt LLC
$82
Merck Sharp & Dohme Corporation
$64
Novartis Pharmaceuticals Corporation
$63
Vifor Pharma, Inc.
$61
PFIZER INC.
$59
Shionogi Inc
$57
Inogen, Inc.
$51
La Jolla Pharmaceutical Company
$50
Advanced Respiratory, Inc
$38
Covis Pharma GmBH
$38
Baxter Healthcare
$38
Teva Pharmaceuticals USA, Inc.
$36
ABIOMED
$36
Philips North America LLC
$35
HOSPIRA, INC.
$30
JAZZ PHARMACEUTICALS INC.
$30
Paratek Pharmaceuticals, Inc.
$27
INOGEN, INC.
$25
Alexion Pharmaceuticals, Inc.
$25
CSL Behring
$25
Bio Products Laboratory USA, Inc.
$18
Axsome Therapeutics, Inc.
$18
Tactile Systems Technology Inc
$18
Avadel CNS Pharmaceuticals, LLC
$18
Lilly USA, LLC
$17
Amgen Inc.
$17
Mallinckrodt Enterprises LLC
$16
BOSTON SCIENTIFIC CORPORATION
$15
SANOFI PASTEUR INC.
$14
Allergan, Inc.
$13
Janssen Pharmaceuticals, Inc
$13
PORTOLA PHARMACEUTICALS, INC.
$12
Phadia US Inc.
$12
PORTOLA PHARMACEUTICALS, LLC
$11
Circassia Pharmaceuticals Inc
$11
Top 3 companies account for 36.6% of all-time payments
Associated products mentioned in payments ›
(7999) SRC Und · (AK6) Vest Therapy · ACTHAR · AIRSUPRA · ALVESCO · ANDEXXA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Arikayce · BEVESPI AEROSPHERE · BEVYXXA · BREO · BREZTRI · BREZTRI AEROSPHERE · DIFICID · DUPIXENT · Dymista · ELIQUIS · Esbriet · FASENRA · FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE · Fetroja · Flexitouch Plus · GENERAL BRONCHIAL THERMOPLASTY · GIAPREZA · GLASSIA · Gammaplex · HYQVIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Hizentra · IMFINZI · INOGEN · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · ImmunoCAP · Impella · LOKELMA · LONHALA MAGNAIR · LUMRYZ · Life 2000 Ventilation System · MOUNJARO · NUCALA · NUZYRA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OFIRMEV · OPSUMIT · OPSUMIT MACITENTAN · PANZYGA · PREVNAR - 13 · Perforomist · Prolastin-C Liquid · SMARTVEST · SOLIRIS · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Soliris · Sunosi · TAGRISSO · TAVNEOS · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Volara System · UPTRAVI · UTIBRON · UTIBRON NEOHALER · Utibron · Veklury · Veltassa · Wellcentive Undiv · XARELTO · XOLAIR · Xembify · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
17
Per 100K population
4.4
County median income
$65,541
Nearest hospital
NOVANT HEALTH FORSYTH MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Defeo is a clinical cardiology specialist, with above-average Medicare volume (top 15% in NC), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Defeo experienced with expiratory airflow and volume test?
Based on Medicare claims data, Dr. Defeo performed 309 expiratory airflow and volume test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Defeo receive payments from pharmaceutical companies?
Yes. Dr. Defeo received a total of $5,682 from 54 companies across 337 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Defeo's costs compare to other pulmonary diseases in Winston Salem?
Dr. Defeo's average Medicare payment per service is $73. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Defeo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Winston Salem
Browse pulmonary diseases in Winston Salem ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NC
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NC
Which NC pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology